Press Releases
-
Galapagos and Dart Neuroscience LLC sign drug discovery and compound management agreements (1.1 MB)
December 9, 2008 -
Helicon Study of HT-0712 on Primate Memory Formation Reveals Significant Enhancement (1.1 MB)
July 22, 2008 -
Inflazyme Pharmaceuticals does not Exercise Option with Helicon Therapeutics to PDE4 Inhibitor, IPL455,903, in Learning and Memory Disorders (1.1 MB)
August 24, 2007 -
Results with PDE4 Inhibitor, IPL455,903, May Merit Further Clinical Evaluation. Data Support Uniqueness of Inflazyme's PDE4 Inhibitors (1.1 MB)
June 26, 2007 -
Inflazyme and Helicon Initiate the Phase IIa Clinical Trial with IPL455,903 in Age Associated Memory Impairment (1.1 MB)
March 2, 2006 -
Inflazyme Pharmaceuticals Announces Results from Helicon's Phase Ib Multi-Dose Study with PDE4 Inhibitor; IPL455,903 Reported to be Save and Well Tolerated (1.1 MB)
November 23, 2005 -
Helicon Therapeutics, Inc. Commences Phase I Human Testing of the Company's Lead Drug Candidate (1.1 MB)
December 10, 2004 -
Helicon Therapeutics Exercises Option to License Compound for Memory Disorders from Inflazyme (1.1 MB)
January 22, 2003 -
Institute for the Study of Aging Funds Helicon Therapeutics to Test New Treatments for Dementia-Researchers Look at Unique Role of Protein in Memory Function (1.1 MB)
September 26, 2001
